All In Biotech

Drug Trial Radar · NCT06472076

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

A Randomized, Multicenter, Double-blind, Phase 3 Study to Investigate the Safety and Efficacy of Belrestotug in Combination With Dostarlimab Compared With Placebo in Combination With Pembrolizumab in Participants With Previously Untreated, Unresectable, Locally Advanced or Metastatic PD-L1 Selected Non-small Cell Lung Cancer (GALAXIES Lung-301)

Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

88

Actual

Start

Jun 10, 2024

Primary completion

Jun 30, 2026

Study completion Aug 30, 2027

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
iTeos Therapeutics
First posted
Jun 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety and tolerability profile of dostarlimab in combination with belrestotug when compared with pembrolizumab and placebo in participants with previously untreated, unresectable, locally advanced or metastatic PD-L1 high NSCLC.

Conditions

  • Lung Cancer, Non-Small Cell

Interventions

  • DostarlimabBiological

    Dostarlimab will be administered.

  • BelrestotugBiological

    Belrestotug will be administered.

  • PembrolizumabBiological

    Pembrolizumab will be administered.

  • PlaceboDrug

    Placebo will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Up to approximately 138 weeks
  2. Number of Participants with TEAEs or SAEs leading to dose withdrawals or treatment discontinuationTime frame: Up to approximately 138 weeks

Locations

108 sites in 21 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Ocala, Florida

  • GSK Investigational Site

    Honolulu, Hawaii

  • GSK Investigational Site

    Lexington, Kentucky

  • GSK Investigational Site

    Lexington, Kentucky

  • GSK Investigational Site

    Omaha, Nebraska

  • GSK Investigational Site

    Nashville, Tennessee

  • GSK Investigational Site

    Fort Worth, Texas

  • GSK Investigational Site

    Olympia, Washington

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Cipoletti Rio Negro, Argentina

  • GSK Investigational Site

    Ciudad Autonoma de Bueno, Argentina

  • GSK Investigational Site

    Ciudad Autonoma de Buenos Aire, Argentina

  • GSK Investigational Site

    Córdoba, Argentina

  • GSK Investigational Site

    Florida, Argentina

  • GSK Investigational Site

    Mendoza, Argentina

  • GSK Investigational Site

    Rosario, Argentina

  • GSK Investigational Site

    San Miguel de Tucumán, Argentina

  • GSK Investigational Site

    Hasselt, Belgium

  • GSK Investigational Site

    Mont Gaston, Belgium

  • GSK Investigational Site

    Barretos, Brazil

  • GSK Investigational Site

    Belém, Brazil

  • GSK Investigational Site

    CuritibaPR, Brazil

  • GSK Investigational Site

    Florianópolis, Brazil

  • GSK Investigational Site

    Fortaleza, Brazil

  • GSK Investigational Site

    Londrina, Brazil

  • GSK Investigational Site

    Porto VelhoRondOnia, Brazil

  • GSK Investigational Site

    Salvador, Brazil

  • GSK Investigational Site

    SAo JosE Do Rio PretoSP, Brazil

  • GSK Investigational Site

    São Paulo, Brazil

  • GSK Investigational Site

    Vitória, Brazil

  • GSK Investigational Site

    Haskovo, Bulgaria

  • GSK Investigational Site

    Plovdiv, Bulgaria

  • GSK Investigational Site

    Halifax, Nova Scotia, Canada

  • GSK Investigational Site

    Chengdu, China

  • GSK Investigational Site

    Hangzhou, China

  • GSK Investigational Site

    Hangzhou, China

  • GSK Investigational Site

    Hefei, China

  • GSK Investigational Site

    Nanjing, China

  • GSK Investigational Site

    Shanghai, China

  • GSK Investigational Site

    Kuopio, Finland

Showing 40 of 108 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.